发明授权
- 专利标题: HbA1c dehydrogenase
-
申请号: US16094924申请日: 2017-04-21
-
公开(公告)号: US11111517B2公开(公告)日: 2021-09-07
- 发明人: Atsushi Ichiyanagi , Yosuke Masakari
- 申请人: Kikkoman Corporation
- 申请人地址: JP Noda
- 专利权人: Kikkoman Corporation
- 当前专利权人: Kikkoman Corporation
- 当前专利权人地址: JP Noda
- 代理机构: Foley & Lardner LLP
- 优先权: JPJP2016-086592 20160422
- 国际申请: PCT/JP2017/016058 WO 20170421
- 国际公布: WO2017/183717 WO 20171026
- 主分类号: C12Q1/32
- IPC分类号: C12Q1/32 ; C12N15/09 ; C12M1/40 ; G01N33/483 ; G01N27/416 ; G01N33/49 ; G01N27/327 ; C12N9/88 ; C12Q1/00 ; G01N33/72 ; C12N9/02
摘要:
This invention provides an HbA1c dehydrogenase that is capable of directly acting on hemoglobin A1c and is less likely to be influenced by oxygen concentration and a method for measurement and a kit of assay reagents using such HbA1c dehydrogenase. The HbA1c dehydrogenase having dehydrogenase activity and capable of directly acting on HbA1c is obtained by substitution of one or more amino acid residues at positions corresponding to positions 280, 269, 54, 241, and 267 of the amadoriase that is capable of directly acting on hemoglobin A1c and is derived from, for example, the genus Coniochaeta. This invention also provides a method for measurement of HbA1c, a kit of assay reagents, and a sensor using such HbA1c dehydrogenase. Such HbA1c dehydrogenase is capable of directly acting on hemoglobin A1c and has lowered oxidase activity and/or enhanced dehydrogenase activity. This not only eliminates the need for treatment of hemoglobin A1c with a protease but also enables the use of an electron mediator in the measurement of HbA1c, thereby reducing effects due to oxygen concentration, and enables HbA1c measured with high sensitivity.
公开/授权文献
- US20190119715A1 HbA1c DEHYDROGENASE 公开/授权日:2019-04-25
信息查询